Potential Benefits
- Rapid anti-inflammatory action (hours to days)
- Gut barrier support
GutBarrier FunctionInflammationSkin QualityGut inflammation / IBD-type support
RESEARCH REFERENCE
KPV
α-MSH C-terminal tripeptide fragment with potent anti-inflammatory effects, especially in the gut.
01
Quick Reference
- Dose
- Oral 500 mcg–1 mg; SC 250–500 mcg
- Frequency / schedule
- 1–2× daily
- Route
- Oral (preferred for gut) or subcutaneous
- Timing
- Flexible (empty stomach preferred for oral)
- Fasting
- Oral best on empty stomach; SC flexible
- Cycle
- 4–8 weeks
- Time off
- 2–4 weeks off
- Common vial strengths
- 5 mg, 10 mg
02
How this works
KPV enters cells and inhibits IκB kinase, blocking NF-κB translocation. This reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). It is preferentially taken up via the PepT1 transporter in inflamed intestinal tissue, making oral use particularly relevant for gut applications.
03
Benefits + side effects
Side Effects
- Generally mild; limited human data
02
Dosing / Protocol
Reference Protocol
| Phase / week | Dose | Frequency | Timing | Notes |
|---|---|---|---|---|
| Gut | 500 mcg | 1–2× daily | Empty stomach | Oral preferred |
| Systemic | 250–500 mcg | 1–2× daily | Flexible | SC |
Timing + Fasting Notes
Oral: empty stomach preferred for better PepT1 uptake. SC: any time.
03
Reconstitution
Approved preparation example
5 mg + 2 mL BAC → 2.5 mg/mL
04
Practical Reference
- Storage
- Refrigerated reconstituted
- Route / injection context
- Oral (preferred for gut) or subcutaneous
- Bloodwork / markers
- CRP, calprotectin (if gut)
- Common vial strengths
- 5 mg, 10 mg
- Cycle / time off
- 4–8 weeks · 2–4 weeks off
- Practical notes
- Often stacked with BPC-157 for gut. Research use only.
10
References
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology · 2008 · DOI 10.1053/j.gastro.2007.10.026
PRECLINICALTHE SIGNAL · SENT TWICE A MONTH